GlassScriptPhysician profile
Alan Barton Halsey
NPI 1790765626
$242,885.90
in general payments reported to CMS, 2019-2025
44 companies · $9,752 in 2025
The $9,752 reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $24K · 2021: $40K · 2022: $45K · 2023: $55K · 2024: $4,822 · 2025: $9,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $9,978 · Consulting Fee: $2,695 · Travel and Lodging: $2,268 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,514.50 |
| Food and Beverage | $9,978.02 |
| Consulting Fee | $2,695.00 |
| Travel and Lodging | $2,267.83 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $75,858.81 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $66,285.51 | 2019-2025 | Dupixent |
| Genzyme Corporation | $56,461.70 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $28,369.02 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Amgen INC. | $7,062.07 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $1,529.98 | 2020-2025 | Cuvitru, Glassia, Hyqvia |
| Csl Behring | $1,028.81 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $854.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $837.29 | 2019-2025 | |
| Genentech USA, INC. | $646.15 | 2019-2025 | Xolair |
| Kaleo, INC. | $568.32 | 2019-2023 | Auvi-Q |
| Welch Allyn | $476.32 | 2021 | |
| Octapharma USA, INC. | $464.22 | 2019-2022 | |
| Blueprint Medicines Corporation | $331.03 | 2023-2024 | Ayvakit |
| Pharming Healthcare, INC. | $273.21 | 2019-2025 | Ruconest |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Halsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.